.png "United Therapeutics (NASDAQ: UTHR)")
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Hold rating on United Therapeutics (NASDAQ: UTHR), with a price target of $95. The company’s shares closed yesterday at $110.86.
Fein noted:
“Our price target of $95/share is based on an equally weighted composite of (a) $98/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $5.78 discounted back to and (b) an NPV of $92/share, discount rate 12.5%, growth rate -2%.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 10.3% and a 44.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Currently, the analyst consensus on United Therapeutics is a Moderate Buy with an average price target of $153.50, which is a 38.5% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Hold rating on the stock with a $106 price target.
.
See today’s analyst top recommended stocks >>
Based on United Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $173 million. In comparison, last year the company had a net profit of $276 million.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.
Read More on UTHR:
